Item 5. Other Information

During the quarter ended March 29, 2025, none of our officers or directors adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K, except as follows:

• On February 19, 2025, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 26, 2024, for the sale of up to 129,721 shares of common stock. Mr. Foster had sold 25,000 shares, pursuant to his Rule 10b5-1 trading arrangement, on August 1, 2024. Absent such termination, the Rule 10b5-1 trading arrangement would have expired on June 30, 2026.

• On March 6, 2025, Mr. Foster entered into a Rule 10b5-1 trading arrangement for the sale of up to 168,463 shares of common stock. The arrangement’s expiration date is August 21, 2027.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

• On February 19, 2025, Ms. Birgit Girshick, our Corporate Executive Vice President and Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated November 22, 2023, for the sale of up to 22,362 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2025.

• On March 3, 2025, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 31,314 shares of common stock. The arrangement’s expiration date is August 31, 2026.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.